Related Experiment Video

Updated: Aug 21, 2026

Generation of Prostate Cancer Cell Models of Resistance to the Anti-mitotic Agent Docetaxel
06:44

Generation of Prostate Cancer Cell Models of Resistance to the Anti-mitotic Agent Docetaxel

Published on: September 8, 2017

PCDHGB2 promotes docetaxel resistance in prostate cancer via TR4-mediated activation of the HIF-1α/VEGFA pathway

Fanyu Meng1, Xinyi Zhou2, Yong Qin1

  • 1Department of Urology, Hangzhou Red Cross Hospital, 208 East Huancheng Road, Hangzhou, 310000 Zhejiang Province China.

Cytotechnology
|August 20, 2026
PubMed

Insights

Prostate cancer (PC) resistance to docetaxel is a major challenge. This study identifies PCDHGB2 as a key driver of docetaxel resistance by interacting with TR4, impacting the HIF-1α/VEGFA pathway.

Area of Science:

  • Oncology
  • Molecular Biology
  • Genomics

Background:

  • Prostate cancer (PC) is a significant global health concern.
  • Docetaxel (DTX) resistance in PC limits treatment efficacy.
  • Understanding resistance mechanisms is crucial for improved therapies.

Purpose of the Study:

  • To identify genes associated with docetaxel resistance in PC.
  • To elucidate the molecular mechanisms of docetaxel resistance.
  • To explore PCDHGB2 as a potential therapeutic target.

Main Methods:

  • Integrated transcriptomic and clinical data (TCGA-PRAD, GEO).
  • Bioinformatics analysis of PCDHGB2 expression, tumor microenvironment, and prognosis.
  • Experimental validation: RT-qPCR, immunofluorescence, CCK-8, co-immunoprecipitation, molecular docking.

Main Results:

  • Identified PCDHGB2 as a pivotal gene in docetaxel resistance.
  • PCDHGB2 expression correlates with tumor microenvironment heterogeneity and invasiveness.
  • PCDHGB2 binds to TR4, activating the HIF-1α/VEGFA pathway, driving chemoresistance.

Conclusions:

  • PCDHGB2 is a central mediator of docetaxel resistance in PC.
  • A novel epigenetic mechanism involving PCDHGB2, TR4, and HIF-1α/VEGFA is identified.
  • Findings offer a framework for improved prognostic strategies in PC.
Keywords:
DocetaxelPCPCDHGB2TR4

More Related Videos

An Orthotopic Murine Model of Human Prostate Cancer Metastasis06:48

An Orthotopic Murine Model of Human Prostate Cancer Metastasis

Published on: September 18, 2013

Related Concept Videos

Regulation of Angiogenesis and Blood Supply01:24

Regulation of Angiogenesis and Blood Supply

Rapidly dividing tumors, embryos, and wounded tissues require more oxygen than usual, lowering the oxygen concentration in the blood. At low oxygen or hypoxic conditions, an oxygen-sensitive transcription factor called the hypoxia-inducible factor 1 or HIF1 is activated. HIF1 is a dimeric protein of alpha (ɑ) and beta (β) subunits.  Under optimal oxygen conditions, HIF1β is present in the nucleus while HIF1ɑ remains in the cytosol. HIF1ɑ is hydroxylated by prolyl hydroxylase and factor...
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...